Androgen Receptor Rearrangement and Splicing Variants in Resistance to Endocrine Therapies in Prostate Cancer

Abstract excerpt

In the last few years, the survival of patients with castration-resistant prostate cancer (CRPC) has significantly improved as a result of the development of second-generation androgen deprivation therapies such as abiraterone and second-generation antagonists such as enzalutamide. However, CRPC patients rapidly develop resistance to these drugs, in many cases because of reactivation of the therapeutic target,...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Estrogen and related hormone effects
• Share to Hormonal and reproductive studies
• Share to Prostate Cancer Treatment and Research